Neurocrine Biosciences director Sherwin sells $1.6m in stock
Stephen A. Sherwin, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.4 billion biopharmaceutical company with strong financials and a healthy current ratio of 3.4, sold 13,831 shares of ...
Neurocrine Biosciences chief legal officer sells $254,991 in stock
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently disclosed stock transactions in a filing with the Securities and Exchange Commission. On February 13, ...
FiercePharma5d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...